In vivo activity of daptomycin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection

International Journal of Antimicrobial Agents

Volumn 45, Issue 2, 2015, Pages 188-191

  Yang, Haifei ^a   Chen, Guosheng ^a   Hu, Lifen ^a   Liu, Yanyan ^a,b   Cheng, Jun ^a   Li, Hongru ^c   Ye, Ying ^a,b   Li, Jiabin ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Center for Surveillance of Bacterial Resistance   (China)

^c Central South University   (China)

Author keywords

Antimicrobial synergy; Daptomycin; Invertebrate model; Polymyxins

Indexed keywords

AMIKACIN; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CHINA; CONTROLLED STUDY; DRUG EFFICACY; GALLERIA MELLONELLA; IN VIVO STUDY; INVERTEBRATE MODEL; LARVA; MICROTITER PLATE ASSAY; MULTIDRUG RESISTANCE; NONHUMAN; SURVIVAL RATE; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMAL; DISEASE MODEL; DRUG COMBINATION; ISOLATION AND PURIFICATION; LEPIDOPTERA; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; LEPIDOPTERA;

EID: 84921464392     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.10.012     Document Type: Article

References (14)

1. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010;35:219-26.
2. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67:1607-15.
3. Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2014;43:370-4.
4. Phee L, Hornsey M, Wareham DW. In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. Eur J Clin Microbiol Infect Dis 2013;32:1291-4.
5. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering Jr RC, Mylonakis E. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 2009;53:2605-9.
6. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 2006;44:2974-6.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. In: Document M100-S24. Wayne, PA: CLSI; 2014.
8. Hornsey M, Longshaw C, Phee L, Wareham DW. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother 2012;56:3080-5.
9. Milne KE, Gould IM. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother 2010;65:82-90.
10. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51.
11. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318-23.
12. Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011;66:1047-51.
13. Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 2011;55:3534-7.
14. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, et al. Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 2013;57:2103-8.